Restless legs syndrome: Treatment with dopaminergic agents

Neurology

Volumn 58, Issue 4 SUPPL. 1, 2002, Pages

  Comella, Cynthia L ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dopaminergic agents; Restless legs syndrome; Treatment

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LONG ACTING DRUG; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

AGING; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DOSE CALCULATION; DRUG EFFICACY; DRUG RESISTANCE; DYSESTHESIA; HUMAN; LEG MOVEMENT; LONG TERM CARE; NAUSEA; NIGHT; PARESTHESIA; PREVALENCE; PRIORITY JOURNAL; REBOUND; REST; RESTLESS LEGS SYNDROME; REVIEW; SLEEP DISORDER; SOMNOLENCE;

CLINICAL TRIALS; DOPAMINE AGENTS; DOPAMINE AGONISTS; HUMANS; RESTLESS LEGS SYNDROME;

EID: 0037176802     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.58.suppl_1.s87     Document Type: Review

References (57)

1. Toward a better definition of the restless legs syndrome
2. Restless legs syndrome: Clinico-etiologic correlates
3. Circadian rhythm of periodic limb movements and sensory symptoms of restless legs syndrome
4. Prevalence and risk factors of RLS in an elderly population: The MEMO study
5. A questionnaire study of 138 patients with restless legs syndrome: The NightWalker's Survey
6. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: A study of 133 patients diagnosed with new standard criteria
7. Familial restless legs with periodic movements in sleep: Electrophysiologic, biochemical, and pharmacologic study
8. Clinical symptoms and possible anticipation in a large kindred of familial restless legs syndrome
9. Variable expressivity in familial restless legs syndrome
10. Sleep disturbance in spinocerebellar ataxia. Is the SCA3 mutation a cause of restless legs syndrome?
11. Clinical and biochemical findings in uremic patients with and without restless legs syndrome
12. Restless legs syndrome in end-stage renal disease
13. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome
14. Etiology and treatment of restless legs syndrome
15. Treatment of restless legs syndrome with levodopa plus benserazide
16. Restless legs syndrome treatment with dopaminergic drugs
17. Restless legs syndrome and periodic movements in sleep: Physiopathology and treatment with L-dopa
18. The treatment of the restless legs syndrome with or without periodic leg movements in sleep
19. Restless legs syndrome and periodic leg movements in sleep: The primary role of dopaminergic mechanisms
20. Rapid onset of action of levodopa in restless legs syndrome: A double-blind, randomized, multicenter, crossover trial
21. A doubleblind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene
22. Levodopa in restless legs
23. Long-term effect of dopaminergic drugs in restless legs. A 2-year follow-up
24. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: A double-blind, controlled study
25. Dopaminergic agents in restless legs syndrome and periodic limb movements of sleep: Response and complications of extended treatment in 49 cases
26. Periodic leg movement, 5-hydroxytryptophan and L-tryptophan
27. Augmentation of the restless legs syndrome with carbidopa/levodopa
28. L-dopa therapy of uremic and idiopathic restless legs syndrome: A double-blind, crossover trial
29. Double-blinded, placebo controlled comparison of propoxyphene and carbidopa/levodopa for treatment of periodic limb movements in sleep
30. Dopaminergic treatment of restless legs and rebound phenomenon
31. A controlled study of additional SR-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms
32. A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome
33. Treatment of Restless legs syndrome with pergolide - An open clinical trial
34. Randomized, double-blind, placebo-controlled trial of pergolide in restless legs syndrome
35. Pergolide: Treatment of choice in restless legs syndrome and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-dopa
36. Pergolide: Treatment of choice in restless legs syndrome and nocturnal myoclonus syndrome. Long-term follow up on pergolide
37. Pergolide in the management of restless legs syndrome: An extended study
38. A randomized controlled study of pergolide in patients with restless legs syndrome
39. A randomized long-term placebo-controlled multicenter trial of pergolide in the treatment of restless legs syndrome with central evaluation of polysomnographic data
40. A randomized long-term placebo-controlled multicenter trial of pergolide in the treatment of RLS with central evaluation of polysomnographic data
41. The safety of pergolide in the treatment of restless legs syndrome (RLS): Results of randomized long-term multicenter trial of pergolide in the treatment of RLS
42. The safety of pergolide in the treatment of restless legs syndrome (RLS): Results of a randomized long-term multicenter trial of pergolide in the treatment of RLS
43. Encouraging initial response of restless legs syndrome to pramipexole
44. Effect of pramipexole in treatment of resistant restless legs syndrome
45. Restless legs syndrome improved by pramipexole: A double-blind randomized trial
46. Pramipexole in the treatment of restless legs syndrome: A follow-up study
47. RLS augmentation and pramipexole long-term treatment
48. Pramipexole in the management of restless legs syndrome: An extended study
49. Ropinirole for restless legs syndrome
50. Ropinirole for the restless legs syndrome (RLS): An open-label and double-blind placebo-controlled study
51. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality
52. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables
53. Effectiveness of the D2-agonist cabergoline as a single-drug therapy for restless legs syndrome: Clinical and actigraphic evaluation
54. Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline - An open clinical trial
55. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder
56. Amantadine is beneficial in restless legs syndrome
57. Treatment of periodic leg movement disorder and restless legs syndrome with talipexole